{"id":17830,"date":"2020-04-30T08:11:39","date_gmt":"2020-04-30T07:11:39","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=17830"},"modified":"2020-04-30T08:19:08","modified_gmt":"2020-04-30T07:19:08","slug":"ukens-ansatt-lars-herfindal","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/nb_no\/2020\/04\/30\/ukens-ansatt-lars-herfindal\/","title":{"rendered":"[:no]Ukens ansatt- Lars Herfindal[:en]This week\u2019s employee – Lars Herfindal[:]"},"content":{"rendered":"

[:no]\"\"<\/a><\/p>\n

Kan du fortelja litt om deg sj\u00f8lv og arbeidsoppg\u00e5vene dine?<\/strong><\/p>\n

Eg har vore tilsett her som professor i farmakologi i snart fem \u00e5r. F\u00f8r det var eg forskar i gruppa til Stein Ove D\u00f8skeland, der eg ogs\u00e5 tok doktorgrad i cellebiologi. Arbeidet mitt er todelt, undervising og forsking. Eg har ansvaret for farmakologiundervisninga for farmas\u00f8ytar. Det er eit utfordrande tema \u00e5 undervisa i, for det kjem stadig nye legemiddel som ein m\u00e5 f\u00e5 med. Samstundes er det sv\u00e6rt l\u00e6rerikt, og ein f\u00e5r nytte av fleire fagdisiplinar, som fysiologi, patofysiologi, cellebiologi, biokjemi, legemiddelkjemi, for \u00e5 nevna nokre. Heldigvis har eg dyktige medarbeidarar som hjelper meg med \u00e5 dra lasset. M\u00e5let v\u00e5rt er \u00e5 stadig forbetra undervisninga, slik at farmas\u00f8ytane f\u00e5r eit godt grunnlag for praktisk bruka av farmakologi n\u00e5r dei skal ut i arbeid.<\/p>\n

Forsking tar sj\u00f8lvsagt mykje tid, og er ein livsstil og ein hobby (lystbetont aktivitet som ein gjer p\u00e5 fritida utan \u00e5 f\u00e5 betalt) like mykje som arbeid. I l\u00f8pet av tida her har eg bygd opp forskingsaktiviteten rundt utvikling av nye behandlingsformer for kreft, med fokus p\u00e5 nye molekyl, og nanomedisin. Me har ogs\u00e5 sett opp system der me nyttar sebrafisk-larver for \u00e5 finna b\u00e5de toksisitet og effektivitet av nye molekyl og nanopartiklar. Med meg i forskinga har eg ei lita gruppe med PhD-studentar, masterstudentar og forskarar, som tar seg av mesteparten av det praktiske arbeidet. Sj\u00f8lv tr\u00f8r eg til n\u00e5r det trengs, men mesteparten av tida er eg nok p\u00e5 kontoret.<\/p>\n

Eg er s\u00e5 heldig \u00e5 f\u00e5 vera med p\u00e5 fleire samarbeidsprosjekt som arbeider med legemiddelutvikling. Det er sv\u00e6rt inspirerande \u00e5 m\u00f8ta dyktige forskarar innan andre fagfelt, som kan utfylla mine kunnskapshol.<\/p>\n

Kvifor likar du \u00e5 jobba p\u00e5 K2?<\/strong><\/p>\n

Eg s\u00f8kte meg til K2 av di eg s\u00e5g at det var eit variert forskingsmilj\u00f8, og kompetanse som gjorde at eg kunne utvikla meg som forskar. Sj\u00f8lv om det p\u00e5 mange m\u00e5tar er likt Institutt for Biomedisin, der eg kom fr\u00e5, er n\u00e6rleiken til klinikken ein stor fordel p\u00e5 K2. Eg har f\u00e5tt h\u00f8ve til \u00e5 samarbeida med klinikarar, som gjer at forskinga mi br\u00e5tt kjem mykje n\u00e6rmare pasienten. Det er ogs\u00e5 mange trivelege folk ved K2, og mange som hjalp meg i gang rett etter eg byrja her. Utan den hjelpa, hadde det vore mykje tyngre for meg \u00e5 komma i gang med forskinga mi. Vidare trivst eg med varierte arbeidsoppg\u00e5ver, og friheit til \u00e5 f\u00f8lgja mine eigne forskingsinteressar. Eg vil ogs\u00e5 legga til at undervisning faktisk er ganske kjekt, s\u00e5 lenge ein f\u00e5r nok tid til \u00e5 f\u00f8rebu seg. Alt i alt er K2 ein fin stad \u00e5 vera.[:en]\"\"Can you tell us something about your daily tasks and work in general?<\/strong><\/p>\n

I have been appointed here as a professor of pharmacology for almost five years. Prior to that, I was a member of the group of Stein Ove D\u00f8skeland, where I also earned a Doctorate in Cell Biology. My work is twofold, teaching and researching. I have responsibility of teaching<\/span> pharmacology for pharmacists. It is a challenging field, consisting of several disciplines, such as physiology, pathophysiology, cell biology, biochemistry, drug chemistry, to mention some. Luckily, I have skilled co-workers who help me pull the load. Our goal is to constantly prepare for teaching, so that pharmacists have a good basis for practical use of pharmacology when going to work.<\/span><\/p>\n

Research takes time, and is a way of life and a hobby (pleasure-staking activity that you do in your spare time) as much as work. During the time here I have built up the research activity around the development of new therapies for cancer, focusing on new molecules, and nanomedicine. We have also looked up systems where we use zebrafish larvae to find both the toxicity and effectiveness of new molecule sandand. With me in the research I have a small group of PhD students, master-student\u00a0 and researchers , who take care of most of the practical work. It’s a good time when it’s needed, but most of the time is enough in the office.
\nI’m so lucky to be part of several collaborative project working on drug development. It is very inspiring to meet skilled researchers in other disciplines, who can fill in my knowledge hole.<\/p>\n

What do you like working at K2?<\/strong><\/p>\n

I applied to K2 because I saw that it was a varied research environment, and expertise that allowed me to develop as a researcher. Although it is in many ways similar to the Department of Biomedicine, where I came from, the close-up of the clinic is a huge advantage at K2. I’ve had the opportunity to work with clinicians, who make sure that my research abruptly come much more closer to the patient. There are also a lot of people at K2, and a lot of people who helped me get started right after I started here. Without that help, it would be much harder for me to get started with my research. I would also add that teaching is actually quite nice, so long as they get enough time to prepare. All in all, K2 is a nice place to work.[:]<\/p>\n","protected":false},"excerpt":{"rendered":"

[:no] Kan du fortelja litt om deg sj\u00f8lv og arbeidsoppg\u00e5vene dine? Eg har vore tilsett her som professor i farmakologi i snart fem \u00e5r. F\u00f8r det var eg forskar i gruppa til Stein Ove D\u00f8skeland, der eg ogs\u00e5 tok doktorgrad…<\/p>\n

Read more →<\/a><\/p>\n","protected":false},"author":4474,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-17830","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/17830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/users\/4474"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/comments?post=17830"}],"version-history":[{"count":7,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/17830\/revisions"}],"predecessor-version":[{"id":17868,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/17830\/revisions\/17868"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/media?parent=17830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/categories?post=17830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/tags?post=17830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}